Yutiq approved in China for chronic noninfectious uveitis
Click Here to Manage Email Alerts
China’s Center for Drug Evaluation of the National Medical Products Administration approved Yutiq for chronic noninfectious uveitis affecting the posterior segment, EyePoint Pharmaceuticals and OcuMension announced in a press release.
Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg is the first drug approved for commercialization in China based entirely on real-world data and the first drug approved for commercial use in OcuMension’s pipeline, the release said.
“Yutiq’s approval in China marks an important milestone for EyePoint and OcuMension’s shared mission of bringing sustained-release drug delivery treatments to patients with debilitating diseases of the eye,” Nancy Lurker, CEO of EyePoint Pharmaceuticals, said in the release. “Since Yutiq’s U.S. approval over 3 years ago, EyePoint has been able to deliver this innovative ocular therapy and provide an improved standard of care for patients by providing up to 3 years of continuous control in chronic noninfectious uveitis affecting the posterior segment of the eye. We are proud to partner with OcuMension and expand Yutiq’s global reach in the emerging Chinese market as we work together to improve the lives of patients with serious eye disorders.”
The FDA approved Yutiq for use in the U.S. in October 2018.
Read more about
Click Here to Manage Email Alerts